A Phase III double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of Drug A in patients with moderate to severe chronic back pain.
Explore related content and topics

Join PRA in China
The expertise of a global CRO + local know-how to deliver the highest caliber of clinical development services around the world.

COVID-19 Kicks Healthcare Technology Adaptation into High Gear
From telemedicine to decentralized clinical trials to artificial intelligence and beyond, the COVID-19 crisis has kicked the use of technology in the…